Biotech MannKind (Nasdaq: MNKD) is one of the health care sector's top performers, approaching a double in 2014 and has notched two year gains over 250%. But what is next for investors in the industry darling?

After FDA approval for its flagship inhaled insulin product Afrezza, it appears the bulls have completely vanquished the MannKind bears -- or are the bears merely licking their substantial wounds, waiting to make another swipe at shares? Because while it may seem like smooth sailing for the biotech now that it has a unique product and an effective monopoly in a huge indication, there is one key question remaining: how will it sell?

In this episode of Where the Money Is, health care analysts David Williamson and Michael Douglass  discuss what MannKind investors should expect next, the kind of patients MannKind should target, and which big pharma makes the most sense as a partner or potential acquirer. Watch and find out.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.